Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia
β Scribed by Thomas G. Pretlow; Theresa P. Pretlow; Bin Yang; Charlotte S. Kaetzel; Carrie M. Delmoro; Sheryl M. Kamis; Donald R. Bodner; Elroy Kursh; Martin I. Resnick; Edwin L. Bradley Jr
- Publisher
- John Wiley and Sons
- Year
- 1991
- Tongue
- French
- Weight
- 775 KB
- Volume
- 49
- Category
- Article
- ISSN
- 0020-7136
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Prostateβspecific antigen (PSA), as measured in peripheral blood, is currently the most widely used marker for the assessment of tumor burden in the longitudinal study of patients with carcinoma of the prostate (PCA). Studies from other laboratories have led to the conclusion that a given volume of PCA causes a much higher level of PSA in the peripheral circulation of patients than a similar volume of prostate without carcinoma. We have evaluated PSA in the resected tissues immunohistochemically and in extracts of PCA and of prostates resected because of benign prostatic hyperplasia (BPH) with an enzymeβlinked immunosorbent assay. Immunohistochemical results were less quantitative than but consistent with the results of the ELISA of tissue extracts. Immunohistochemically, there was considerable heterogeneity in the expression of PSA by both PCA and BPH both within and among prostatic tissues from different patients. While the levels of expression of PSA in these tissues overlap broadly, PSA is expressed at a lower level in PCA than in BPH when PSA is expressed as a function of wet weight of tissue (p = 0.0095), wet weight of tissue/% epithelium (p < 0.0001), protein extracted from the tissue (p = 0.0039). or protein extracted/% epithelium (p < 0.0001).
π SIMILAR VOLUMES
## Abstract ## BACKGROUND The distribution of prostateβspecific antigen (PSA) values for men with or without prostate carcinoma are confounded because of verification bias. Correcting for verification bias, the means and variances of PSA values were estimated in specific clinical scenarios. ## ME